American Society of Hirudotherapy

The haemostatic role of tissue factor pathway inhibitor.

Review published in Arteriosclerosis, thrombosis, and vascular biology (2007)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDrug DevelopmentSalivary PharmacologyCrawley et al. · Arteriosclerosis, thrombosis, and vascular biology, 2007

Abstract

Under normal conditions the blood circulates freely within the confines of the vascular system, carrying oxygen, nutrients, and hormonal information around the body and removing metabolic waste. If blood gains access to extravascular sites, or the vasculature becomes pathologically challenged, hemostasis may be activated. This process is finely regulated by positive and negative feedback loops that modulate fibrin clot formation. Blood coagulation revolves around the activation and assembly of the components of the prothrombinase complex, which converts the inactive zymogen, prothrombin, into its active form, thrombin. This serine protease catalyzes the conversion of fibrinogen to fibrin, the structural scaffold that stabilizes platelet aggregates at sites of vascular injury. The extent of the hemostatic response is controlled by the action of inhibitory pathways, which ensure that thrombin activity and the spread of the hemostatic plug is limited to the site of vessel damage. This review article focuses on the major physiological regulator of tissue factor-induced coagulation, tissue factor pathway inhibitor, its expression, anticoagulant function, and its role in normal hemostasis.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov'tReview
Indexed MeSH termsFactor XaGene Expression ProfilingHemostasisHumansLipoproteinsSerine EndopeptidasesStructure-Activity Relationship

Summary

Under normal conditions the blood circulates freely within the confines of the vascular system, carrying oxygen, nutrients, and hormonal information around the body and removing metabolic waste. If blood gains access to extravascular sites, or the vasculature becomes pathologically challenged,...

Why This Matters for Hirudotherapy

This review article examines the physiological role of tissue factor pathway inhibitor (TFPI) in regulating tissue factor-induced coagulation and maintaining hemostatic balance. It describes how TFPI modulates thrombin generation and limits clot propagation to sites of vascular injury. For ASH, the article provides background on endogenous anticoagulant pathways that parallel some mechanisms of leech-derived anticoagulants such as hirudin, offering context for understanding the broader coagulation cascade that leech secretome components interact with. CAVEAT: This review contains no direct discussion of leeches, hirudin, hirudotherapy, or any leech-derived compounds; its relevance is strictly indirect as general coagulation biology background.

Citation

The haemostatic role of tissue factor pathway inhibitor.

Crawley et al. · Arteriosclerosis, thrombosis, and vascular biology, 2007

DOI

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.